Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
BACKGROUND Axillary reverse mapping (ARM) is a novel technique for preserving the upper extremity lymphatic pathways during axillary lymph node surgery. However, there is no evidence of the… Continue Reading
No clinical evidence on the efficacy and safety of eribulin monotherapy has been obtained by a prospective clinical study in patients with metastatic breast cancer (MBC) who had well-defined taxane… Continue Reading
OBJECTIVES Indicators of ischemic heart disease were studied for the practice of preventive medicine. METHODS Intravascular ultrasonography was performed in 97 patients with no abnormalities by… Continue Reading
OBJECTIVES The aim of this study was to identify risk factors for rupture of unruptured cerebral aneurysms (UCAs) in elderly Japanese patients aged 70 years or older. METHODS The participants… Continue Reading
BackgroundEribulin mesylate is currently indicated as a sequential monotherapy to be administered after two chemotherapeutic regimens, including anthracycline and taxane treatments, for treatment of… Continue Reading
OBJECTIVE Combined therapy with bevacizumab and paclitaxel (BP regimen) as a first-line treatment has proven highly effective with good tolerance for patients with metastatic breast cancer (MBC). The… Continue Reading
Background ARG098, a chimeric anti-Fas IgM monoclonal antibody, possesses a novel mode of action totally different from those of currently available RA therapeutics including cytokine targeting… Continue Reading
BackgroundThis phase II neoadjuvant study evaluated the efficacy and safety of a triweekly regimen of docetaxel and carboplatin in combination with trastuzumab (TCbH) in Japanese women with human… Continue Reading
BACKGROUND/AIM Published data have shown that palbociclib-fulvestrant can significantly improve the progression-free survival (PFS) of estrogen receptor-positive/human epidermal growth factor… Continue Reading
[This corrects the article on p. 179 in vol. 4, PMID: 26005649.].